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Clinical guidelines recommend reporting estimated glomerular filtration rate (eGFR) from serum 
creatinine measurements using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation, still organizations report eGFR mainly using alternative equations.  
Objective:  
To evaluate the risk relationship of eGFR from the CKD-EPI equation relative to the 
Modification of Diet in Renal Disease (MDRD) and Mayo Clinic Quadratic (MCQ), describe 
differences in interpretation of eGFR values, and implications associated with switching to the 
CKD-EPI equation, in a large patient population receiving ambulatory care in the United States.  
Results:  
Overall, 4.5 million patients aged 18–99 were included in the study, with 37,000 events for 
ESRD and 195,000 for all-cause mortality. The average eGFR was considerably lower for CKD-
EPI (82.7 ml/min/1.73m2) and MDRD (79.7 ml/min/1.73m2), compared to MCQ (94.9 
ml/min/1.73m2). Accordingly, the prevalence of GFR category 3–5 (<60 mL/min/1.73 m²) was 
15.8% with CKD-EPI, 17.3% with MDRD, and 6.4% with MCQ. The CKD-EPI equation had a 
similarly steep risk gradient to the MDRD equation in GFR 3-5 range, both steeper than the risk 
gradient for the MCQ equation. The risk gradient at higher estimates of GFR was steeper for the 
CKD-EPI equation relative to MDRD, but shallower than MCQ. The CKD-EPI equation, 
compared to MDRD, reclassified more patients upward to higher categories of eGFR (2.6% 
downward vs.15.7% upward), and many more patients downward to lower categories compared 
to the MCQ (39.1% downward vs. 1.3% upward). Net reclassification improvement favored the 
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CKD-EPI to MDRD equation for ESRD (0.12) and all-cause mortality (0.19), and favored the 
CKD-EPI to MCQ for all-cause mortality (0.06) but not ESRD (‒ 0.07).  
Conclusion: 
Regarding risk stratification, the recommended CKD-EPI equation is superior to MDRD. Similar 
estimates of GFR from the two equations, especially in GFR 3–5 range, facilitate transitioning to 
the CKD-EPI equation from MDRD. MCQ largely shifted the distribution of eGFR and eGFR-
risk relationship to higher levels of eGFR, warranting its careful interpretation particularly at 
referral or transition from or to facilities using other equations.  
Advisor: Josef Coresh, MD, PhD 
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In the United States, approximately 14% of adults have chronic kidney disease (CKD) which is 
estimated to cost $49 billion to treat annually.1, 2 Less than 10% of adults in GFR category 1–3 
are aware of their renal impairment, and less than half even for GFR category 4.3 Early detection 
of CKD is important to slow down or prevent progression to kidney failure, avoid nephrotoxic 
medications, and reduce overall morbidity and mortality.4 
Glomerular filtration rate (GFR) measures the rate at which the kidneys filter the blood 
and is considered the gold standard for evaluating kidney function. GFR can be measured by 
administrating a filtration marker, generally through injection or infusion, and measuring the 
presence of the filtration marker during a clearance period through repeated measurements (e.g., 
urine or blood), but is considered too cumbersome and costly for day to day monitoring of 
kidney function. Thus, estimated GFR (eGFR) using endogenous filtration markers from a blood 
sample is generally considered an accepted alternative.5, 6 
Serum creatinine (SCr) is one of the components of the basic metabolic panel, a 
commonly ordered lab in primary care, and when combined with demographics (e.g., age, sex, 
and race), can be used to estimate GFR. Kidney Disease: Improving Global Outcomes (KDIGO): 
Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 
recommends using serum creatinine for eGFR.7 In addition to the diagnosis and management of 
CKD, eGFR is used to determine contraindications and avoid nephrotoxic medications, e.g., 
metformin, a first line therapy for diabetes contraindicated in patients with eGFR < 30 (and not 
generally recommended < 60 mL/min/1.73 m²).8 
In response to recommendations by guidelines for use of estimating equations7-9, clinical 
laboratories reporting eGFR with creatinine measurements have increased dramatically in the 
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last 15 years (3% in 2003 to 89% in 2017).10 Guidelines recommend reporting eGFR in adults 
using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine 
equation to diagnose and stage CKD with known risk relationships.7, 8 Still a survey in 2017 
found the majority of laboratories report eGFR using equations no longer (or never) 
recommended by guidelines, mainly the Modification of Diet in Renal Disease (MDRD) 
equation, or other less frequently used equations, e.g., Mayo Clinic Quadratic (MCQ).10  
While all three equations require serum creatinine to estimate GFR, the CKD-EPI and 
MDRD are expressed for use with standardized assays (e.g., traceable to isotope dilution mass 
spectrometry), while the MCQ is not. In addition to serum creatinine, the CKD-EPI and MDRD 
equations require age, sex, and race, whereas the MCQ equation requires age and sex only. Since 
2011, meaningful use has incentivized the systematic collection and standardization of race in 
electronic health records (EHR), facilitating the transition for health care organizations to using 
the CKD-EPI equation, from other estimating equations which ignore race.11, 12  
Prior studies suggest relative to measured GFR, estimates from the CKD-EPI equation 
are more accurate than those from MDRD, most recently established in a systematic review of 48 
studies with primary care populations.13 A study comparing the accuracy of the CKD-EPI, 
MDRD, and MCQ equations directly among solid organ transplant recipients, found the CKD-
EPI and MDRD more accurate than the MCQ equation, which overestimated kidney function.14 
Other studies among kidney donors,15, 16 and in a clinical setting,17 found the MDRD equation 
more accurate than MCQ. While among patients with diabetes, the MCQ was more accurate, but 
only for patients with higher estimates of kidney function.18, 19  
It has been established that the CKD-EPI equation more accurately categorizes risk of 
adverse events than the MDRD equation in a broad range of populations,20-25 but these studies 
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did not include the MCQ equation. Research among 500,000 middle aged Swedish men and 
women, found a stronger risk association with myocardial infarction and all-cause mortality for 
GFR values estimated with the MCQ equation, compared to MDRD.26 Two other studies found a 
similar relationship with risk of mortality and coronary artery disease for the CKD-EPI and 
MCQ equations, both stronger than MDRD.27, 28  
Electronic heath record data from health care organizations provide the opportunity to 
compare estimating equations and their ability to risk-stratify patients and describe the 
implications of switching to the recommended CKD-EPI, from the MDRD or MCQ equations, 
using “real world” serum creatinine measurements from a large and diverse patient population. 
The goal of this study was to compare eGFR calculated with the CKD-EPI equation relative to 
the MDRD and MCQ equations, for classification of end stage renal disease (ESRD) and all-
cause mortality risk, and describe the implications associated with using the different estimating 
equations on a large patient population receiving ambulatory care in the United States. Results 
from this study will contribute to information from prior research on the relative ability of 
creatinine based estimating equations to classify risk of adverse events, describe how 
interpretation of eGFR values differ between equations, and provide implications for switching 
equations to the CKD-EPI, from MDRD or MCQ. These provide useful evidence to patients, 
health care organizations and providers, clinical laboratories, researchers, policy makers, among 
others. 
2 Methods 
2.1 Data Source 
This study was conducted using longitudinal EHR data from 25 health care organizations, a 
subset of Optum Analytics’ clinical data asset. The organizations who contribute data are 
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integrated delivery systems, multispecialty medical groups, and academic faculty practices that 
are members of AMGA and participate in a learning collaborative, AMGA Analytics for 
Improvement, focused on enhancing value in population health. These organizations are diverse 
in size (~100 to 2,000 FTE physicians), structure, geography, and patient demographics. 
The Optum Analytics EHR database, derived from a variety of different EHR systems and 
normalized across health care organizations, contains longitudinal, patient-level detail, including 
clinical observations (e.g., blood pressure, body mass index), laboratory measurements (e.g., 
hemoglobin A1c, cholesterol, serum creatinine), medical procedures, diagnoses (on a claim, e.g.,  
for an evaluation and management ambulatory visit, or on the patient’s problem list in the EHR), 
medications (using prescriptions or the patient’s medication list in the EHR), physician notes, 
patient reported outcomes (e.g., smoking, physical activity, pain score), demographics (e.g., age, 
race, ethnicity, gender), socio-demographics (imputed from five-digit zip code), healthcare 
utilization metrics (e.g., office visits, inpatient admissions), and other data collected in the course 
of health care delivery. 
2.2 Study Population 
Patients with data between 01/01/2012 – 09/30/2017 were eligible for this study. We 
implemented the baseline period of at least 15 months to capture data of covariates. Then, we 
identified the first creatinine measurement after the baseline period, which corresponded to the 
index date for follow-up for clinical outcomes. Patients with no outcomes during the follow-up 
period were censored on the date of their last office visit after index date (Figure 1). We 
excluded patients younger than 18 and older than 99 years from this study, as well as those with 
evidence of ESRD prior to the index date. Patients with less than 3 months of follow-up were 




Figure 1: Study Schema 
 
2.3 Covariates 
2.3.1 Clinical measurements 
Systolic blood pressure  
Systolic blood pressure (BP) was taken in an ambulatory setting, when multiple blood pressures 
were taken on the same day, the lowest value was kept, and when there were multiple days in the 
baseline period with measurements, we used data from the day closest to the index date. Methods 
of measurement and precision of BP vary by health care organization, e.g., some use automated 
BP machines, and other manual sphygmomanometer. Most health care organizations 
contributing data were concurrently participating in a national campaign focused on improving 
hypertension screening, control, and detection, lasting the majority of the study period, including 
emphasis on proper measurement of BP and screening for high BP.29  
Smoking 
Smoking status was defined as current smoker, previous smoker, or never smoker based on 
patient-reported data. For patients with conflicting data on smoking status during the baseline 
period, e.g., a record for current smoker followed by one for never smoker, the more “severe” 
smoking status is used, i.e., any patient with status of current smoker during the baseline period, 
was classified as such regardless of other evidence. 
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2.3.2 Comorbid Conditions 
Diagnosis codes were defined with 9th and 10th revisions of the International Classification of 
Diseases (ICD-9 and ICD-10) and identified on a claim or the patients’ problem list in the EHR. 
Procedure codes were defined with Current Procedural Terminology (CPT) and identified on a 
claim, and medications were available at the class level, identified on prescriptions and the 
patients’ medication list in the EHR. 
Cardiovascular disease 
Cardiovascular disease (CVD) was defined using diagnosis codes or procedure codes for 
myocardial infarction (old or new), coronary artery bypass graft, percutaneous coronary 
intervention, heart failure, or stroke.  
Diabetes mellitus  
Diabetes mellitus was defined using diagnosis codes for type 1, type 2, or secondary diabetes 
(due to underlying conditions, chemical or drug induced, or other specified), or complications 
attributed to diabetes (diabetic retinopathy or cataract, polyneuropathy in diabetes, or diabetic 
nephropathy). The following medication classes were also used to define diabetes: sulfonylureas, 
thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 agonist, 
sodium/glucose cotransporter 2, or insulin.  
Hypertension  
Hypertension was defined using diagnosis codes for essential or secondary hypertension, or a 
prescription for a medication used to treat hypertension: angiotensin-converting enzyme (ACE) 
inhibitor, angiotensin II receptor blocker (ARB), beta blocker, calcium channel blocker, 





Defined on the index date in integer years.  
Health care organization 
Deidentified code for each organization, which was used in our models to account for 
correlations between patients receiving care within the same health care organization. 
Race/Ethnicity 
Asian, Black, Hispanic/Latino, White, Other, or unknown/missing 
Sex 
Female or Male 
2.4 Exposure 
2.4.1 Serum Creatinine 
For patients with multiple serum creatinine measurements taken on the index date, we used the 
lowest value. Precision of serum creatinine measurements was described using the proportion of 
values with a 0 in the second place after the decimal (e.g., 0.90, 1.00), where with precise 
measurement, we expect ~10% of patients to end in each digit, including 0. 
2.4.2 Estimated GFR 
Serum creatinine values from the index date, and the necessary demographics were used to 
estimate GFR with the CKD-EPI,30 MDRD,31 and MCQ32 equations, listed in Figure 2. For the 
same age, sex, and serum creatinine, the CKD-EPI and MDRD estimate higher estimates of 
kidney function for patients who are Black, compared to White or Other race (i.e., not Black). 
Compared to CKD-EPI, the MDRD equation has a larger adjustment for race (1.159 vs. 1.212), 
corresponding to larger differences in estimates of GFR between races for the MDRD equation.  
8 
 
The CKD-EPI and MCQ equations include splines to account for different relationships 
between serum creatinine and GFR at different levels of serum creatinine. For the CKD-EPI 
equation the splines use sex specific knots, while for MCQ the knot at 0.8 mg/dL is used for both 
males and females, and the slope is flat (i.e., equal to 0 when < 0.8 mg/dL). Meaning differences 
between GFR estimates with the MCQ equation when serum creatinine < 0.8 mg/dL are due to 
age and sex.  
        Figure 2: Creatinine Based GFR Estimating Equations  
 
Figure 3 shows the relationship of eGFR and serum creatinine by race for the CKD-EPI, 
MDRD, and MCQ estimating equations, for female patients aged 75 years. The solid lines in the 
bottom left corner show the serum creatinine values which correspond to estimates in GFR 
category 2 (60–89 mL/min/1.73 m²) for each equation and race. Serum creatinine values in GFR 
category 2 with the CKD-EPI and MDRD equations are similar for Black patients, and for White 
or Other race the range is slightly wider for the CKD-EPI equation (CKD-EPI: 0.59‒0.93, 
MDRD: 0.64–0.92 mg/dL). Using the MCQ equation, a female patient aged 75 will never have 
an estimate in GFR category 1 (≥ 90 mL/min/1.73 m²), and all patients with serum creatinine ≤ 
1.20 mg/dL have estimates in GFR category 2. Compared to the CKD-EPI and MDRD 
equations, the MCQ estimates lower GFR for the smallest values of serum creatinine, e.g., < 0.7 




Figure 3: Estimated GFR (eGFR) for Females Aged 75, by Serum Creatinine 
(SCr), Race, and Equation 
 
The dark red and blue lines show the relationship for Black patients, and the light red and blue lines for non-
Black patients, for the CKD-EPI and MDRD equations respectively. The green line reflects the relationship for 
all females aged 75 using the MCQ equation. The smaller box towards the top right of the figure focuses on 
the range of SCr corresponding to estimates of GFR of the lowest kidney function, e.g., 1.1-5.0 mg/dL.  
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet 
in Renal Disease; MCQ, Mayo Clinic Quadratic 
GFR 2 Range: eGFR 60-89 mL/min/1.73 m² 
 
2.5 Follow-up/Outcomes  
End stage renal disease (ESRD)  
End stage renal disease was defined using diagnosis and procedure codes for dialysis, kidney 
transplant, or ESRD.  
All-cause mortality  
All-cause mortality was defined using the date of death field from the EHR. Dates were limited 
to month and year of death and assumed to occur on the 15th day.  
Follow-up time 
For ESRD and all-cause mortality separately, patient’s accumulated follow-up time from the 
index date to the first evidence of the outcome. 
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2.6 Statistical Methods 
2.6.1 eGFR Distribution and Classification 
Distributions from the CKD-EPI, MDRD, and MCQ equations were compared continuously, 
using deciles (i.e., eGFR values for the 10, 20, 30, 40, 50, 60, 70, 80, 90th percentile), and using 
clinically meaningful eGFR categories (i.e., eGFR < 15, 15–29, 30–44, 45–59, 60–89, and ≥ 90 
mL/min/1.73 m²).7  
2.6.2 Hazard Ratios 
Risk of ESRD and all-cause mortality was evaluated using unadjusted and adjusted hazard ratios 
estimated from Cox proportional hazards regression models. All adjusted models were adjusted 
for age (continuous), sex, race (Black vs. Not Black), smoking (never, previous, or current), 
systolic blood pressure (continuous), and history of cardiovascular disease, diabetes, and 
hypertension. All Cox models used cluster-adjusted standard errors to account for correlation 
within healthcare organizations. 
2.6.3 Risk Prediction 
We evaluated the risk relationship separately for each equation and outcome. Estimated GFR 
was included in the model as a continuous variable with 7 linear splines and knots at eGFR 30, 
45, 60, 75, 90, and 105 mL/min/1.73 m², as previously modeled, to allow for potentially non-
linear relationship with risk at different levels of eGFR.33 Each equation was compared relative 
to a reference value of 60 mL/min/1.73 m² for the given equation.  
Deciles 
We included eGFR decile in the model as a categorical variable, using the 7th decile (60th to 70th 
percentile) for that given equation as the reference category. 
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2.6.4 Reclassification Matrix 
First, for each equation separately, we compared the risk using crude incidence rates and 
adjusted hazard ratios for eGFR categories previously described, (< 15, 15–29, 30–44, 45–59, 
60–89, and ≥ 90 mL/min/1.73 m²), using GFR 2 (60–89 mL/min/1.73 m²) for the given equation 
as the reference category. Next, comparing the CKD-EPI equation to the MDRD and MCQ 
equations, we cross-tabulated eGFR using the same categories. For each combination of eGFR 
categories we calculated the proportion of the study cohort, crude incidence rate, and adjusted 
hazard ratios using a reference of GFR 2 for both equations.  
2.6.5 Net Reclassification Improvement (NRI)  
Net Reclassification Improvement (NRI) was applied to compare the equations directly. 
Reclassification was calculated using eGFR categories (< 15, 15–29, 30–44, 45–59, 60–89, and 
 ≥ 90 mL/min/1.73 m²), comparing the CKD-EPI equation to the MDRD and MCQ equations 
separately. Results are presented for each outcome and pair of equations, overall and stratified by 
event.34 
Demographic Subgroups  
To assess generalizability of results in different subpopulations we applied NRI to the subgroups 
by age (< 65 vs. ≥ 65), sex (male vs. female), hypertension, diabetes, cardiovascular disease, 
race/ethnicity (White vs. Black vs. Asian vs. Hispanic), and smoking status (current vs. previous, 
vs. never). 
Sensitivity Analyses 
Sensitivity analyses for NRI included calculating net reclassification using eGFR deciles, and 




2.6.6 Missing values 
Missing values for race, smoking, and systolic BP, were imputed using mean values within each 
health care organization.  
2.6.7 Statistical Software 
All statistical analyses were conducting using Stata version 13.1 
3 Results 
3.1 Patient Characteristics 
Table 1 shows overall, 4.5 million patients aged 18–99 with a serum creatinine measurement on 
the index date and no previous evidence of ESRD were included in this study. There was a total 
of 195,000 events for all-cause mortality, 37,000 events for ESRD, and average follow-up time 
was 2.4 years. Average age was 58.4 years, 84.8% White, 8.5% Black, and 58.4% female. 
Overall, there was 61.6% of patients with hypertension, 22.9% with diabetes, and 12.0% with 
cardiovascular disease. Most patients had a measurement for systolic blood pressure (SBP) and 
smoking during the baseline period (96.1% and 92.7%), with average SBP of 125.9 mmHg, 
19.8% current smoker, 24.4% previous smoker, and 48.6% never smoker. Patient characteristics 
were similar between the populations with eGFR CKD-EPI and eGFR MDRD < 60 mL/min/1.73 m², 
and comparatively patients with eGFR MCQ < 60 mL/min/1.73 m² were more likely to develop 











Table 1: Patient Characteristics Overall and by Estimated GFR < 60 
mL/min/1.73 m² 
 
Abbreviations: ESRD, End Stage Renal Disease; SD, standard deviation; eGFR, estimated GFR; 
SCr, serum creatinine; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, 
Modification of Diet in Renal Disease; CVD, Cardiovascular Disease; BP, Blood Pressure  
 
3.2 eGFR Distribution and Classification 
The average eGFR was considerably lower for CKD-EPI (82.7 ml/min/1.73m2) and MDRD 
(79.7 ml/min/1.73m2) compared to MCQ (94.9 ml/min/1.73m2) equation. Accordingly, the 
prevalence of GFR category 3–5 (< 60 mL/min/1.73 m²) was 15.8% with CKD-EPI, 17.3% with 
MDRD, and 6.4% with MCQ. Prevalence for eGFR MCQ < 79 mL/min/1.73 m² was 15.9%. 
Average eGFR CKD-EPI for patients with eGFR CKD-EPI < 60 was 47.3 mL/min/1.73 m², while for 
patients with eGFR MCQ < 60 mL/min/1.73 m² average eGFR CKD-EPI was 37.6 mL/min/1.73 m². 
Comparing the distributions of eGFR from the three estimating equations in Figure 4, the MCQ 
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equation shifts the population to higher GFR estimates (category 1: CKD-EPI, 40.1%; MDRD, 
28.8%; MCQ 66.1%).   
Figure 4: Distribution of Estimated GFR using the CKD-EPI, MDRD, and MCQ 
Equations 
 
3.3 Continuous Risk Association  
In Figure 5, the CKD-EPI and MDRD equations had a similar relationship with risk of ESRD 
and all-cause mortality when eGFR < 90 ml/min/1.73 m2. For eGFR > 90 ml/min/1.73 m2, 
hazard ratios were smaller (farther from the null, < 1.0) for estimates from the CKD-EPI 
compared to the MDRD equation. After adjusting for risk factors, the risk gradient at higher 
estimates of GFR was still steeper for CKD-EPI compared to MDRD, for ESRD but not all-
cause mortality. 
 Comparing the CKD-EPI and MCQ equations, the risk gradient of estimated GFR with 
ESRD and all-cause mortality was steeper for CKD-EPI in GFR category 3–5 range (eGFR < 60 
ml/min/1.73 m2) and shallower when eGFR ≥ 75 ml/min/1.73 m2, even after adjusting for risk 
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factors. For the adjusted models of both ESRD and all-cause mortality hazard ratios were similar 
for the equations when eGFR was between 60 and 75 ml/min/1.73 m2.  
Figure 5: Estimated GFR and Hazard Ratios (HR) of ESRD and All -Cause 
Mortality (ACM) 
 
Error ribbons for each equation indicate 95% confidence intervals for estimated GFR. Reference value is 
estimated GFR of 60 mL/min/1.73m2. Adjusted hazard ratio adjusted for age, sex, race/ethnicity, smoking status, 
history of cardiovascular disease, diabetes, hypertension, systolic blood pressure. Hazard ratios below the dotted 
black line at 1.0 indicate a lower risk of ESRD or all-cause mortality, and above the line a higher risk. 
Abbreviations: ESRD, End Stage Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration; MDRD, Modification of Diet in Renal Disease; MCQ, Mayo Clinic Quadratic 
In general, all three equations estimate patients with the highest risk of ESRD to the lowest 
estimates of GFR. For all-cause mortality each equation in the adjusted models had a J-shape risk 
relationship, where higher eGFR is associated with lower or similar risk of mortality, until eGFR 
≥ 90 ml/min/1.73 m2, with even higher estimates associated with higher risk.  
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3.4 Deciles of eGFR by Estimating Equation and Risk Association 
Estimated GFR values for deciles were similar with the CKD-EPI and MDRD equations in the 
two highest (9 and 10) and lowest deciles (1 and 2), while in between (3–8), deciles for the 
CKD-EPI equation occurred at higher values of eGFR than the equivalent deciles for MDRD. 
The most noticeable differences in crude incidence rates of ESRD and all-cause mortality 
between the CKD-EPI and MDRD equations where in the 8-10th deciles, where incidence rates 
for the CKD-EPI equation continued to decline, while for the MDRD equation rates began to 
increase. Similarly, adjusted hazard ratios for risk of ESRD by deciles showed a consistent risk 
gradient for the CKD-EPI equation, with higher deciles corresponding to lower risk (except from 
the 7th to the 8th decile), while risk increased from the 8th to the 10th decile for MDRD. The 
largest relative differences in hazard ratios for risk of ESRD were in the 9th (AHR CKD-EPI: 0.76 
vs. AHR MDRD: 0.91) and 10
th deciles (AHR CKD-EPI: 0.68 vs. AHR MDRD: 1.08). In contrast, for 
all-cause mortality the CKD-EPI equation had a steeper positive risk gradient in the 8th through 
10th deciles than the MDRD equation. 
Table 2:  eGFR Deciles, Crude Incidence Rates (CIR), and Adjusted Hazard 
Ratios (AHR) 
 
Adjusted hazard ratio adjusted for age, sex, race, smoking status, history of cardiovascular disease, diabetes, 
hypertension, systolic blood pressure, with the 7th decile for the respective equations as the reference category. 
Abbreviations: ESRD, End Stage Renal Disease; ACM, all-cause mortality;  
Crude incidence rates calculated per 1,000 person years. 
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The CKD-EPI and MCQ equations had similar incidence rates of ESRD, and small 
differences in rates for all-cause mortality. Adjusted hazard ratios for ESRD were smaller in the 
3 –6th (towards the null) and 8 –10th deciles (away from the null) for the CKD-EPI equation 
compared to MCQ. For all-cause mortality hazard ratios were similar for both equations except 
in the 10th decile (AHR CKD-EPI: 2.65 vs. AHR MCQ: 1.96). 
3.5 Net Reclassification Improvement (NRI) 
Overall Table 3 shows NRI favored the CKD-EPI to MDRD equation for ESRD (0.12) and all-
cause mortality (0.19). For all-cause mortality, NRI favored the CKD-EPI equation for both 
events (0.05) and non-events (0.14), and for ESRD for non-events only (NRI No ESRD: 0.13 vs. 
NRI ESRD: ‒ 0.02). The most notable differences across subgroups were between age < 65 and ≥ 
65 years, i.e., NRI favored CKD-EPI for reclassification of non-events and MDRD for events 
among patients < 65 (NRI No Event: 0.23 ESRD and 0.23 all-cause mortality , NRI Event: ‒ 0.14 
ESRD and ‒ 0.18 all-cause mortality), and favored CKD-EPI for reclassification of events and 
MDRD non-events among patients ≥ 65 years (NRI Event: 0.05 ESRD and 0.11 all-cause 
mortality, NRI No Event: ‒ 0.03 ESRD, and ‒ 0.03 all-cause mortality).  
Net reclassification improvement favored the CKD-EPI equation for reclassification of 
events and MCQ for non-events of ESRD and all-cause mortality overall, and consistently across 
subgroups. Combining event and non-event NRI, NRI favors the CKD-EPI equation for all-cause 
mortality and MCQ for ESRD (0.06 and ‒ 0.07). Across demographic subgroups, NRI was 
largest in favor of the CKD-EPI equation among females (compared to males) for ESRD, and 
Hispanic, Asian or White patients (compared to Black) for all-cause mortality.  Using deciles to 
calculate reclassification improvement, NRI for events still favored the CKD-EPI equation (0.03 
for ESRD and 0.02 for all-cause mortality) and NRI for non-events the MCQ (‒0.13 for ESRD 
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and ‒0.14 for all-cause mortality), but both values were smaller than the equivalent NRI using 
absolute GFR categories. 
Table 3: Net Reclassification Improvement (NRI) for ESRD and All -Cause 
Mortality (ACM) 
 
Abbreviations: CVD, Cardiovascular Disease; HTN, Hypertension 
NRI calculated using eGFR categories: < 15, 15-29, 30-44, 45-59, 60-89, and ≥ 90 mL/min/1.73 m² 
Positive numbers in orange favor CKD-EPI for reclassification, negative numbers in blue in favor MDRD 
3.6 Reclassification Matrix 
3.6.1 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Compared to 
Modification of Diet in Renal Disease (MDRD) 
Summing the percentages of the study population (top right of each box) in the diagonals from 
Tables 4, overall 81.7% of patients were classified into the same GFR category using the CKD-
EPI and MDRD equations, 15.7% of patients were reclassified upward into categories of higher 
estimated GFR, and 2.6% downward to lower values of GFR. In general patients reclassified 
upward to higher categories of eGFR with the CKD-EPI compared to MDRD equation, were 
younger, less likely to be Black, male, or die, than those classified in the same category with 
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both equations, while patients reclassified downward, were older, more likely to be Black, 
female, and die (Appendix Table 1: Section D, E, I, and K).s 
Patients reclassified downward with the CKD-EPI compared to MDRD equation had a 
higher risk of ESRD and all-cause mortality (values below the diagonal), and patients 
reclassified upward a lower risk (values above the diagonal), except for reclassification to GFR 2 
CKD-EPI  from GFR 1 MDRD which had similar mortality risk to patients in GFR 1 with both 
equations. In the margins of the table, having GFR 1 CKD-EPI was associated with a 40% 
decreased risk of ESRD compared to GFR 2 CKD-EPI, and GFR 1 MDRD (compared to GFR 2 MDRD) 
only a 20% decreased risk. Adjusted hazard ratios for all-cause mortality for GFR category 3–5 
were similar for both equations. 
Table 4: Reclassification, Crude Incidence Rates (CIR), and Adjusted Hazard 
Ratios (AHR), CKD-EPI vs. MDRD 
 
Abbreviations: ESRD, End Stage Renal Disease; ACM, all-cause mortality;  
Crude incidence rates calculated per 1,000 person years. 
Adjusted hazard ratio adjusted for age, sex, race, smoking status, history of cardiovascular disease, diabetes, 
hypertension, systolic blood pressure, with the 7th decile for the respective equations as the reference category. 
3.6.2 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Compared to Mayo 
Clinic Quadratic (MCQ) 
Overall 59.5% of patients were classified into the same GFR category using the CKD-EPI and 
MCQ equations, 1.3% of patients were reclassified upward into categories of higher estimated 
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GFR, and 39.1% downward to lower values of GFR. In general patients reclassified downward 
with the CKD-EPI compared to MCQ equation are older, less likely to be male (except for 
reclassification to GFR 2 CKD-EPI from GFR 1 MCQ) and Black (Appendix Table 2: Section D, E, I, 
and K).), CKD-EPI vs. MDRD 
Table 5: Reclassification, Crude Incidence Rates (CIR), and  Adjusted Hazard 
Ratios (AHR), CKD-EPI vs. MDRD 
 
Abbreviations: ESRD, End Stage Renal Disease; ACM, all-cause mortality;  
Crude incidence rates calculated per 1,000 person years. 
Adjusted hazard ratio adjusted for age, sex, race, smoking status, history of cardiovascular disease, diabetes, 
hypertension, systolic blood pressure, with the 7th decile for the respective equations as the reference category. 
 
Patients reclassified downward with the CKD-EPI compared to MCQ equation had a 
higher risk of ESRD and all-cause mortality (adjusted hazard ratios below the diagonal), and 
patients reclassified upward a lower risk (adjusted hazard ratios above the diagonal), except for 
reclassification to GFR 2 CKD-EPI  from GFR 1 MCQ which had lower mortality risk relative to 
patients in GFR 1 with both equations (AHR 0.9 vs. 1.3), and to GFR 2 CKD-EPI  from GFR 3a MCQ 
which had higher mortality risk (AHR 9.3 vs. 1.3). In the margins of Table 5, crude incidence 
rates for GFR 2 were 1.5 (CKD-EPI) vs. 2.8 (MCQ) ESRD events per 1,000 person years, and 
15.3 (CKD-EPI) vs. 26.7 (MCQ) mortality events per 1,000 person years. Differences in risk 
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gradients with eGFR categories from the CKD-EPI and MCQ equations were similar to those 
from the continuous distributions in Figure 5. 
3.7 Precision of Serum Creatinine Measurements 
The spikes in the serum creatinine distribution in Figure 6 occur every 0.1 mg/dL, e.g., at 0.30, 
0.40, 0.50, 0.60 mg/dL, etc... In our study population, 40.5% of patients had a 0 in the second 
decimal place of their serum creatinine measurement (dark blue). Figure 7 shows across 
individual health care organizations, 6 organizations have serum creatinine measurements almost 
exclusively recorded to the nearest 0.1 mg/dL (97%+ of patients with a 0 as the 2nd decimal), and 
6 organizations have serum creatinine measurements almost exclusively recorded to the nearest 
0.01 mg/dL (10–12% with a 0), the level of precision currently recommended by guidelines for 
clinical laboratories to report serum creatinine.7 
Figure 6: Precision of Serum Creatinine Measurements from Clinical 
Laboratories 
 
Precision of serum creatinine measurements was quantified using the proportion of values with a 0 in the second 
place after the decimal (e.g., 0.90, 1.00 mg/dL). Each color represents a different digit for the second place after the 
decimal (i.e., 0 through 9). The distribution on the left shows the proportion of the study population for the study 
population, and the column on the right is the distribution of digits in the 2nd decimal place. 
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Figure 7: Precision of Serum Creatinine Measurements by Health Care 
Organization 
 
Each column is a different health care organization. Each color represents a different digit for the second place 
after the decimal (i.e., 0 through 9), and percentages reflect the proportion of patients within each health care 




In our study population of 4.5 million patients receiving ambulatory health care in the United 
States, overall the CKD-EPI equation estimated slightly higher GFR values than MDRD, and 
much lower values than the MCQ equation. Patients characteristics were similar among eGFR 
subgroups using the CKD-EPI and MDRD equations, while comparatively for GFR category 3–5 
using the MCQ equation, patients were more likely to be male, Black, and sicker. The CKD-EPI 
equation had a similarly steep risk gradient to the MDRD equation in GFR category 3–5, both 
steeper than the risk gradient for the MCQ equation. Overall, reclassification improvement 
favored the CKD-EPI to MDRD equation for ESRD and all-cause mortality. GFR estimates from 
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the CKD-EPI equation substantially improved reclassification of events compared to estimates 
from the MCQ equation, with almost equally negative reclassification for non-events. 
Our results confirm using “real world” data from diverse patient populations, that while 
staging CKD and determining contraindications for nephrotoxic medications is based on GFR 
estimates, the equation used to estimate GFR should impact the interpretation of values. The 
CKD-EPI and MDRD equations produce similar prevalence for eGFR < 60 ml/min/1.73 m2, 
facilitating a move from the older MDRD equation to the currently recommended CKD-EPI 
equation. The MCQ equation has been shown to overestimate kidney function relative to 
measured GFR in many populations,14-17 and markedly raises the mean level of estimated GFR. 
This complicates comparison and interpretation of values relative to those from measured GFR, 
or more accurate estimates, e.g., from the CKD-EPI equation. 
Results from our models with eGFR as a continuous and categorical variable were 
internally consistent and showed the relationship of estimated GFR with risk of ESRD and all-
cause mortality was similar with estimates from the CKD-EPI and MDRD equation at lower 
estimate of kidney function, and both stronger compared to the MCQ. At higher estimates of 
kidney function the risk relationship was stronger for the CKD-EPI equation relative to MDRD, 
but not quite as strong as the MCQ. Thus, if one focuses on risk gradients in GFR 3–5 range, the 
KDIGO recommended CKD-EPI equation has a similarly steep risk gradient to the MDRD 
equation, both steeper than the risk gradient with the MCQ equation. These results are consistent 
with previous research which have found the CKD-EPI equation more accurately categorizes risk 
of adverse events than the MDRD equation.20-25 We add to the literature comparing the CKD-
EPI and MCQ equations by including ESRD risk. In addition, we show by accounting for the 
shift in GFR estimates between equations, i.e., by using eGFR deciles instead of categories with 
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the same absolute thresholds, the relative risk gradient at higher GFR estimates is steeper and in 
favor of the CKD-EPI compared to MCQ. 
The CKD-EPI equation had positive reclassification for both events and non-events with 
all-cause mortality compared to MDRD. For ESRD the gain for events with MDRD (–0.02) was 
small compared to the loss for non-events (0.13). Compared to the largest study, we showed 
slightly less reclassification, but similar NRI overall and by age group.20 The reclassification 
comparison of the CKD-EPI and MCQ equation is more complicated since the MCQ markedly 
raises the mean level of estimated GFR.  As a result, the CKD-EPI showed substantial favorable 
(> 0.3) reclassification for both ESRD and mortality events but the opposite for non-events  
(< ‒0.3). While previous literature has found similar improvements in NRI by event for all-cause 
mortality,28 in this situation the NRI is difficult to interpret since it places an arbitrarily equal 
weight on their two large and opposite reclassification proportions. Arithmetically, the result is a 
positive NRI for mortality (favoring CKD-EPI) and negative NRI for ESRD (MCQ).  However, 
quantitatively combining opposite reclassification should include a cost-benefit analysis with 
utilities to classifying individuals who will and will not develop ESRD at different GFR stages.  
The J-shape risk association between estimated GFR for all three equations and risk of 
mortality is present in the adjusted models but not the unadjusted ones and can be primarily 
accounted for with adjustment for age. This is something that has been studied in the past and 
may be caused by a loss of muscle mass secondary to ill-health, corresponding to lower values of 
serum creatinine and better estimates of kidney function.23 This is a limitation to estimating 
equations based on filtration markers related to muscle mass, e.g., serum creatinine. 
One limitation of this study is data collection for serum creatinine was a part of clinical care, 
with variability in precision of measurements reported by clinical laboratories. While KDIGO 
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guidelines recommend labs report serum creatinine to the nearest 0.01 mg/dL, almost a quarter of 
health care organizations had measurements recorded exclusively by to the nearest 0.1 mg/dL. 
While there is evidence serum creatinine measurements are imprecise, this does not give any 
indication towards the accuracy of these measurements. No information was provided on 
standardization of serum creatinine calibration measurements to isotope dilution mass 
spectrometry, but prior research suggest by 2011, a year before the start of our dataset, 
standardization was in large part achieved by clinical laboratories.10 
Another limitation was ascertainment of outcomes, i.e., ESRD using diagnosis and 
procedure codes, and all-cause mortality using date of death in the patients’ electronic health 
record. These methods might be considered suboptimal to other methods, e.g., linking to the 
United States Renal Data System, or social security death index. Finally, our study included 
short follow-up which could impact generalizability of our results to longer term risk of ESRD 
and mortality. 
Strengths of this study include the size of the study population and number of events, as well 
as the availability of data on risk factors. This “real-world” from diverse patient populations, 
allowed us to compare the equations among lesser studied subgroups. Another strength is its 
generalizability to patients receiving ambulatory care in the United States health care system, 
providing valuable information to health care providers and organizations on the implications of 
switching to the CKD-EPI equation from the MDRD or MCQ.  
5 Conclusions 
 
Our conclusion is that based on these risk data alone, the recommended CKD-EPI equation is 
superior to MDRD in classifying risk of ESRD and all-cause mortality. Similar estimates of GFR 
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from the two equations, especially in CKD range (GFR category 3‒5), facilitate transitioning to 
the CKD-EPI equation from MDRD.  
MCQ largely shifted the distribution of eGFR and eGFR-risk relationship to higher levels 
of eGFR. The markedly different absolute values reported with each equation, make it difficult 
for health care providers to translate recommendations based on one equation to another. While 
risk classification with the CKD-EPI equation, which is currently recommended by clinical 
guidelines to stage CKD with known risk relationships, is not superior to the MCQ equation, 
using the MCQ equation in an ambulatory setting would require significant considerations and 
adjustments for bias of GFR estimates, potentially introducing unnecessary risks of adverse 
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Appendix Table 1: Patient Characteristics by Reclassification- CKD-EPI vs. 
MDRD 
 




Appendix Table 3: Appendix Table 1: Patient Characteristics Overall and by 
Estimated GFR ≥ 60 with each Equation  
 
Abbreviations: ESRD, End Stage Renal Disease; SD, standard deviation; eGFR, estimated GFR; SCr, serum 
creatinine; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal 
Disease; CVD, Cardiovascular Disease; BP, Blood Pressure 
Appendix Table 4: Alternative Net Reclassification Improvement Using Deciles 
and in eGFR Subgroups 
 
Net reclassification improvement was evaluated by comparing eGFR deciles between equations. 
eGFR CKD-EPI < 60 and ≥ 60 mL/min/1.73 m² was evaluated using bias corrected NRI, which adjusts for the expected 
reclassification under the null hypothesis, i.e., symmetric reclassification on either side of the diagonal, and allows 
us to compare NRI in subgroups determined by one of the two equations being compared. 
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